Cellceutix Expands to Gram-Negative Bacterial Infections
March 05 2014 - 06:00AM
Marketwired
Cellceutix Expands to Gram-Negative Bacterial Infections
BEVERLY, MA--(Marketwired - Mar 5, 2014) - Cellceutix
Corporation (OTCQB: CTIX) (the "Company"), a clinical stage
biopharmaceutical company developing innovative therapies in
oncology, dermatology, and antibiotic applications, is pleased to
inform shareholders that several preclinical investigations are
underway with several lead compounds in animal models of
Gram-negative bacterial infections. The Company is focusing
this research on some of the most difficult to treat multi-drug
resistant or "pandrug-resistant" bacterium where there is a
significant and growing medical need for new therapies.
One set of studies are being done with systemically-administered
compounds in tissue infection models with multi-drug resistant
Klebsiella pneumoniae. Specific drug-resistant strains of
Klebsiella bacteria have rendered today's approved antibiotics
completely ineffective, including carbapenems, the last line of
defense for Gram-negative drug-resistant bacteria.
A second set of studies is being conducted with
topically-administered compounds in models of superficial and deep
tissue wounds, such as those encountered on the battlefield.
Infecting organisms include multi-drug resistant Pseudomonas
aeruginosa and Acinetobacter baumannii. Acinetobacter is an
example of long-known bacteria that has now mutated into thousands
of resilient strains that thrive in jagged combat wounds, with many
resistant to even the most powerful antibiotic treatments available
today.
The lead Cellceutix compounds in both sets of studies are small
mimics of the host defense proteins that have been discovered to be
potently active against these challenging pathogens. The
studies are being conducted at a university laboratory.
"Gram-negative infections represent a growing and significant
medical need. The organisms included in these studies
represent some of the most difficult-to-treat pathogens due to
their resistance to available antibiotics," commented Dr. Krishna
Menon, Chief Scientific Officer at Cellceutix. "The
$560-million agreement between Roche and Polyphor in November for a
Phase 2 drug and $191 million-plus deal with Discuva the
other week for a technology to discover new therapies
highlights just how valuable a new multi-drug resistant
Gram-negative antibiotic is today."
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Cellceutix is pleased to report that all four U.S. sites in its
phase 2b Acute Bacterial Skin and Skin Structure Infection
(ABSSSI) clinical trial are now screening and enrolling
patients.
About Cellceutix: Headquartered in Beverly, Massachusetts,
Cellceutix is a publicly traded company under the symbol "CTIX".
Cellceutix is a clinical stage biopharmaceutical company developing
innovative therapies in oncology, dermatology and antibiotic
applications. Cellceutix believes it has a world-class portfolio of
compounds and is now engaged in advancing its compounds and seeking
strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is
currently in a Phase 1 clinical trial at Harvard Cancer Centers'
Dana Farber Cancer Institute and Beth Israel Deaconess Medical
Center. In the laboratory Kevetrin has shown to induce
activation of p53, often referred to as the "Guardian Angel Gene"
due to its crucial role in controlling cell mutations. Cellceutix
is planning a Phase 2 clinical trial with its novel compound
Brilacidin-OM for the prevention and treatment of Oral
Mucositis. Brilacidin-OM, a defensin mimetic compound, has
shown in the laboratory to reduce the occurrence of severe
ulcerative oral mucositis by more than 94% compared to placebo.
Cellceutix's anti-psoriasis drug Prurisol is being readied for
clinical trials at sites in the U.S. and Europe. Prurisol is a
small molecule that acts through immune modulation and PRINS
reduction. Cellceutix's key antibiotic, Brilacidin, has begun a
Phase 2b trial in February 2014 for Acute Bacterial Skin and Skin
Structure Infections, or ABSSSI. Brilacidin has the potential to be
a single-dose therapy or a dosing regimen that is shorter than
currently marketed antibiotics for multi-drug resistant bacteria
(Superbugs). Cellceutix has formed research collaborations with
world-renowned research institutions in the United States and
Europe, including MD Anderson Cancer Center, Beth Israel Deaconess
Medical Center, and the University of Bologna. More information is
available on the Cellceutix web site at www.cellceutix.com
Forward-Looking Statements This press release contains
forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
that involve risks, uncertainties and assumptions that could cause
Cellceutix's actual results and experience to differ materially
from anticipated results and expectations expressed in these
forward looking statements. Cellceutix has in some cases identified
forward-looking statements by using words such as "anticipates,"
"believes," "hopes," "estimates," "looks," "expects," "plans,"
"intends," "goal," "potential," "may," "suggest," and similar
expressions. Among other factors that could cause actual results to
differ materially from those expressed in forward-looking
statements are Cellceutix's need for, and the availability of,
substantial capital in the future to fund its operations and
research and development; including the amount and timing of the
sale of shares of common stock to Aspire Capital; the fact that
Cellceutix's compounds may not successfully complete pre-clinical
or clinical testing, or be granted regulatory approval to be sold
and marketed in the United States or elsewhere. A more complete
description of these risk factors is included in Cellceutix's
filings with the Securities and Exchange Commission. You should not
place undue reliance on any forward-looking statements. Cellceutix
undertakes no obligation to release publicly the results of any
revisions to any such forward-looking statements that may be made
to reflect events or circumstances after the date of this press
release or to reflect the occurrence of unanticipated events,
except as required by applicable law or regulation.
Contact: INVESTOR AND MEDIA CONTACT: Cellceutix Corp. Leo
Ehrlich (978) 236-8717 Email Contact
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Innovation Pharmaceuticals (PK) (USOTC:IPIX)
Historical Stock Chart
From Mar 2023 to Mar 2024